A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

Trial Profile

A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms ESPRIT
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 01 Sep 2017 7-year interim analysis of the ESPRIT registry (n=6051), results published in the Dermatology and Therapy
    • 26 Sep 2016 Interim results will be presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), as per AbbVie media release.
    • 08 Mar 2016 Six year interim results presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top